Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790181 | 1.00 | HRH4 (0.53) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL14693243 | 1.00 | HRH4 (0.53) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL13667194 | 1.00 | HRH4 (0.53) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL14693345 | 0.99 | HRH4 (0.54) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL13667253 | 0.99 | HRH4 (0.54) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL14693242 | 0.97 | HRH4 (0.51) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL13667200 | 0.97 | HRH4 (0.51) | HRH4HRH3CXCR4ADRB1PRKD1 | |
| SCHEMBL13666989 | 0.93 | HRH4 (0.55) | HRH4HRH3ADRB1PRKD1PRKD2 | |
| SCHEMBL13668864 | 0.93 | HRH4 (0.55) | HRH4HRH3ADRB1PRKD1PRKD2 | |
| SCHEMBL13668486 | 0.88 | HRH4 (0.54) | HRH4HRH3CXCR4PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372849-B2 | Heterocyclic compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-02-12 | — | — | US | disclosed |
| WO-2009131598-A1 | HETEROCYCLIC COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264339-A1 | Heterocyclic Compounds | AHR, NQO1, LTC4S | HRH4 818/4885HRH3 1566/4885CXCR4 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.